E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
wound healing in diabetes patients with foot ulcer |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048037 |
E.1.2 | Term | Wound healing disturbance of |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effects of a systemic treatment with erythropoietin on wound closure in patients with diabetes and diabetic foot syndrome |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are: a) To evaluate the wound healing, i.e. area of the target (biggest) ulcer, from baseline to week 13 (percentage and absolute change).
b) To evaluate the microcirculation (only at selected study sites).
c) To describe the one-year survival status/amputation rate/recurrence of target ulcer. d) To evaluate the wound healing, i.e. depth of the target ulcer from baseline to week 13. e) To evaluate the time to wound closure. f) To evaluate the reduction of pain. g) Safety and tolerability.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Diabetic patients with foot ulcer below the ankle will be randomised into 2 treatment arms: a. diagnosis of diabetes and neuropathic ulcer Wagner I or II (as indicated by a neuropathy deficit score 6-10, palpable foot pulses and an ABI-index ≥1.0) or b. diagnosis of diabetes and ulcer Wagner I / II or wounds after amputations in patients with peripheral arterial occlusive disease (as indicated by the presence of one of the following: missing foot pulses and an ABI-index ≤0.8), or a history of insufficient vascularisation on the target leg*). *Angiographically documented peripheral arterial occlusive disease and no surgical or endovascular treatment option.
2. Ulcer size over 0.5 cm2. 3. Male or female aged ≥ 18 years. 4. Signed written informed consent to participate in this trial. 5. Female of childbearing potential with a negative pregnancy test, and agrees to use an acceptable contraceptive method (hormonal or IUD) throughout the study. 6. HbA1c < 10% or, if > 10% then stable blood glucose level within the last 4 weeks, i.e. fasting blood glucose value < 160 mg/dl. 7. At least one foot ulcer, the size of which can be documented using a transparent foil. 8. Weight between 55 kg and 160 kg.
9. Patients without significant healing after a 4 week Run-In period, can be randomized into a treatment arm.
|
|
E.4 | Principal exclusion criteria |
1. Pregnant or nursing women. 2. Myeloplastic or proliferative disease. 3. Known infection with hepatitis B or hepatitis C or HIV. 4. Therapy with rHuEPO or analogic medicine within the last 6 months. 5. Bleeding episodes which affect the Hb value or known gastro-intestinale bleedings within the last 3 months. 6. Known or suspected intolerance to erythropoetic factors, e.g. NeoRecormon®, Aranesp®, Erypo®. 7. Treatment with systemic chemotherapy or radiotherapy or immunosuppressives or systemic corticosteroids within the last 6 months prior to treatment start. 8. Previous therapy with growth factors, e.g. GM-CSF, VEGF in the last 6 months. 9. Intake of any medication which interacts with epoetin beta (e.g. Cyclosporin). 10. Uncontrolled systolic blood pressure > 160 mmHg (supine) and/or diastolic blood pressure > 100 mmHg. 11. Pulmonary embolism and deep leg venous thrombosis with a history of venous thromboembolic disease. 12. Stroke, instable angina pectoris, STEMI or NSTEMI within the last 3 month. 13. Psychiatric disease or chronic cerebellar fits. 14. Scheduled for vascular surgery or any other intervention surgery within 4 weeks to trial start or during the trial or patients, who could benefit from vascular surgery or other invasive intervention. 15. Thromboembolism and/or thromboses. 16. Atrial fibrillation or atrial septum defect. 17. Transient ischaemic attack (TIA) within the last 3 month 18. Prolonged reversible ischemic neurological deficit (PRIND) within the last 3 month 19. Artificial heart valves (mechanical or biological) 20. Alcohol or drug of abuse. 21. Non-compliance and/or participation in a clinical trial within the last 3 months prior to screening. 22. Patients in dialysis program or chronical renal failure Grad IV. 23. Patients with known bleedings, MCV below normal ranges, and iron deficiency anemia 24. Hemoglobin, hematocrit and platelet count above the upper limit of normal according to the local laboratory 25. At the time point of randomization wound infections treated with antibiotics.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint is complete wound closure of the target ulcer. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |